NDC 65862-933

NEVIRAPINE

Nevirapine

NEVIRAPINE is a Oral Tablet, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Aurobindo Pharma Limited. The primary component is Nevirapine.

Product ID65862-933_43c85e50-b00a-4758-b69d-52a1b9625dad
NDC65862-933
Product TypeHuman Prescription Drug
Proprietary NameNEVIRAPINE
Generic NameNevirapine
Dosage FormTablet, Extended Release
Route of AdministrationORAL
Marketing Start Date2017-02-28
Marketing CategoryANDA / ANDA
Application NumberANDA207698
Labeler NameAurobindo Pharma Limited
Substance NameNEVIRAPINE
Active Ingredient Strength400 mg/1
Pharm ClassesHuman Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [EXT],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 65862-933-05

500 TABLET, EXTENDED RELEASE in 1 BOTTLE (65862-933-05)
Marketing Start Date2017-02-28
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 65862-933-30 [65862093330]

NEVIRAPINE TABLET, EXTENDED RELEASE
Marketing CategoryANDA
Application NumberANDA207698
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2017-02-28

NDC 65862-933-99 [65862093399]

NEVIRAPINE TABLET, EXTENDED RELEASE
Marketing CategoryANDA
Application NumberANDA207698
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2017-02-28

NDC 65862-933-90 [65862093390]

NEVIRAPINE TABLET, EXTENDED RELEASE
Marketing CategoryANDA
Application NumberANDA207698
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2017-02-28

NDC 65862-933-05 [65862093305]

NEVIRAPINE TABLET, EXTENDED RELEASE
Marketing CategoryANDA
Application NumberANDA207698
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2017-02-28

Drug Details

Active Ingredients

IngredientStrength
NEVIRAPINE400 mg/1

OpenFDA Data

SPL SET ID:de554daa-bdfe-4677-a2ac-0196e0d213bf
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1095712

    • Pharmacological Class

    • Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Non-Nucleoside Analog [EXT]
    • Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Cytochrome P450 3A Inducers [MoA]
    • Cytochrome P450 2B6 Inducers [MoA]

    Medicade Reported Pricing

    65862093330 NEVIRAPINE ER 400 MG TABLET

    Pricing Unit: EA | Drug Type:

    NDC Crossover Matching brand name "NEVIRAPINE" or generic name "Nevirapine"

    NDCBrand NameGeneric Name
    0378-4050Nevirapinenevirapine
    0378-4890Nevirapinenevirapine
    0378-6950Nevirapinenevirapine
    0781-5893NevirapineNevirapine
    31722-505NevirapineNevirapine
    33342-004NevirapineNevirapine
    33342-238NEVIRAPINENEVIRAPINE
    42571-131NEVIRAPINENEVIRAPINE
    51991-331NevirapineNEVIRAPINE
    53104-0166nevirapinenevirapine
    53808-0680Nevirapinenevirapine
    53808-1069nevirapinenevirapine
    61442-470NevirapineNevirapine
    64380-709NevirapineNevirapine
    65162-209NevirapineNevirapine
    69097-403NEVIRAPINENEVIRAPINE
    69097-233nevirapinenevirapine
    65862-057NevirapineNevirapine
    65862-027NevirapineNevirapine
    65862-932NEVIRAPINENEVIRAPINE
    65862-933NEVIRAPINENEVIRAPINE
    47781-317Nevirapine Extended Releasenevirapine
    0597-0046Viramunenevirapine
    0597-0047Viramunenevirapine
    0597-0123Viramunenevirapine
    53808-0808Viramunenevirapine
    © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.